Madan H. Jagasia
Expertise in
20
conditions

Dr. Madan H. Jagasia

Hematology
Office
1301 Medical Center Dr Ste 1710, 
Nashville, TN 
Clinical Trials:Currently Recruiting for 1 Trial
27 Years of Experience
Expertise in
20
conditions
Office
1301 Medical Center Dr Ste 1710, 
Nashville, TN 

Overview

Madan Jagasia is a Hematologist practicing medicine in Nashville, Tennessee. He has been practicing medicine for over 27 years.

Dr. Jagasia is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Multiple Myeloma, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 171 peer reviewed articles and participating in 13 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in TN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
1301 Medical Center Dr Ste 1710, Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: February 25, 2026
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Genetic
A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes
A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib
Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Other, Drug
Study Drug: Ibrutinib
Study Phase: Phase 2
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
Enrollment Status: Completed
Publish Date: January 19, 2023
Intervention Type: Biological
Study Drug: Neihulizumab (AbGn-168H)
Study Phase: Phase 1
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Enrollment Status: Completed
Publish Date: October 21, 2022
Intervention Type: Drug
Study Drugs: Natalizumab, Steroids
Study Phase: Phase 2
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD
Enrollment Status: Completed
Publish Date: July 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
T-regulatory Homing Subsets as a Predictor of Response in GVHD Treated With Extracorporeal Photopheresis
T-regulatory Homing Subsets as a Predictor of Response in GVHD Treated With Extracorporeal Photopheresis
Enrollment Status: Terminated
Publish Date: January 14, 2021
Intervention Type: Procedure, Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

171 Total Publications

Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation.
Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation.
Journal: Cytotherapy
Published: November 10, 2024
Similar Doctors
Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required

Vanderbilt Hematology Clinic

1301 Medical Center Dr Ste 3903, 
Nashville, TN 
 (2.0 miles away)
615-322-5000
Languages Spoken:
English, Hindi, Spanish, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Nishitha Reddy is a Hematologist practicing medicine in Nashville, Tennessee. Dr. Reddy is highly rated in 36 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Reddy is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Vanderbilt Hematology Clinic

1301 Medical Center Dr Ste 3903, 
Nashville, TN 
 (2.0 miles away)
615-322-5000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Savona is a Hematologist practicing medicine in Nashville, Tennessee. Dr. Savona is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelofibrosis, and Bone Marrow Aspiration. Dr. Savona is currently accepting new patients.

Expertise in
5
conditions
Dr. Michael R. Debaun
Hematology | Oncology
Expertise in
5
conditions
Dr. Michael R. Debaun
Hematology | Oncology
Referral may be required

Vanderbilt Children's Hematology-Oncology

2200 Childrens Way # 6, 
Nashville, TN 
 (0.1 miles away)
615-322-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Debaun is a Hematologist and an Oncologist practicing medicine in Nashville, Tennessee. Dr. Debaun is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant. Dr. Debaun is currently accepting new patients.

Frequently Asked Questions about Dr. Madan H. Jagasia

How do I make an appointment with Dr. Madan H. Jagasia?

You can book an appointment with Dr. Madan H. Jagasia by calling their office at 615-936-8422. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Madan H. Jagasia a top-rated expert for Chronic Graft Versus Host Disease (cGvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Madan H. Jagasia is classified as an Elite expert for Chronic Graft Versus Host Disease (cGvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Madan H. Jagasia specialize in?

While Dr. Madan H. Jagasia is a Hematology, they have specific expertise in Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Madan H. Jagasia participate in research or clinical trials?

Yes. Dr. Madan H. Jagasia has published 171 articles and abstracts on conditions like Chronic Graft Versus Host Disease (cGvHD). You can view a list of Dr. Madan H. Jagasia's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jagasia's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 10 Advanced Conditions
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile